Paper35680378
RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
Traber GM and 1 other. J Pharmacol Exp Ther, 2023. Cited by 231 papers, by iCite.
Cite this record
ConductScience Library. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies. Papers, record 35680378. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35680378
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| MicroRNAs | Major topic |
| Biological Products | Major topic |
| RNA Interference | |
| RNAi Therapeutics | |
| RNA, Small Interfering | |
| Bioengineering |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA093373 | NCI NIH HHS | United States | P30CA093373 | PubMed and NIH | NIH RePORTER |
| T32 GM144303 | NIGMS NIH HHS | United States | T32GM144303 | PubMed | NIH RePORTER |
| R01 CA225958 | NCI NIH HHS | United States | R01CA225958 | PubMed and NIH | NIH RePORTER |
| T32 GM099608 | NIGMS NIH HHS | United States | T32GM099608 | PubMed and NIH | NIH RePORTER |
| R35 GM140835 | NIGMS NIH HHS | United States | R35GM140835 | PubMed and NIH | NIH RePORTER |
| R01 CA253230 | NCI NIH HHS | United States | R01CA253230 | PubMed and NIH | NIH RePORTER |
References260
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35326738 | Clinical Applications of Short Non-Coding RNA-Based Therapies in the Era of Precision Medicine. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/35326738 | PubMed |
| 2 | 26756051 | Preface. | Methods Mol Biol | 2016 | https://conductscience.org/library/papers/26756051 | PubMed |
| 3 | 27432743 | An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria. | J Am Soc Nephrol | 2017 | https://conductscience.org/library/papers/27432743 | PubMed |
| 4 | 32187462 | Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32187462 | PubMed |
| 5 | 23982190 | Improved Performance of Anti-miRNA Oligonucleotides Using a Novel Non-Nucleotide Modifier. | Mol Ther Nucleic Acids | 2013 | https://conductscience.org/library/papers/23982190 | PubMed |
| 6 | 28415566 | Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. | Oncotarget | 2017 | https://conductscience.org/library/papers/28415566 | PubMed |
| 7 | 29280958 | Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/29280958 | PubMed |
| 8 | 22610888 | MiR-122 in hepatic function and liver diseases. | Protein Cell | 2012 | https://conductscience.org/library/papers/22610888 | PubMed |
| 9 | 32238921 | Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours. | Br J Cancer | 2020 | https://conductscience.org/library/papers/32238921 | PubMed |
| 10 | 20347954 | Identification of homologous microRNAs in 56 animal genomes. | Genomics | 2010 | https://conductscience.org/library/papers/20347954 | PubMed |
| 11 | 25161167 | Rapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells. | Drug Metab Dispos | 2014 | https://conductscience.org/library/papers/25161167 | PubMed |
| 12 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 13 | 16672282 | Characterization of extracellular RNAs produced by the marine photosynthetic bacterium Rhodovulum sulfidophilum. | J Biochem | 2006 | https://conductscience.org/library/papers/16672282 | PubMed |
| 14 | 28202367 | Exosomes: Therapy delivery tools and biomarkers of diseases. | Pharmacol Ther | 2017 | https://conductscience.org/library/papers/28202367 | PubMed |
| 15 | 17579574 | 2'-O-methyl-modified RNAs act as TLR7 antagonists. | Mol Ther | 2007 | https://conductscience.org/library/papers/17579574 | PubMed |
| 16 | 33405070 | Lumasiran: First Approval. | Drugs | 2021 | https://conductscience.org/library/papers/33405070 | PubMed |
| 17 | 32539351 | Investigational Therapies for Primary Hyperoxaluria. | Bioconjug Chem | 2020 | https://conductscience.org/library/papers/32539351 | PubMed |
| 18 | 28854095 | Porphyria. | N Engl J Med | 2017 | https://conductscience.org/library/papers/28854095 | PubMed |
| 19 | 16816104 | A brief history of RNAi: the silence of the genes. | FASEB J | 2006 | https://conductscience.org/library/papers/16816104 | PubMed |
| 20 | 19239886 | Origins and Mechanisms of miRNAs and siRNAs. | Cell | 2009 | https://conductscience.org/library/papers/19239886 | PubMed |
Cited by168
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 231 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42921028 | Structural and Combinatorial Design Principles of Emerging Drug Carriers. | ACS Bio Med Chem Au | 2026 | https://conductscience.org/library/papers/42921028 | PubMed |
| 42890564 | Nucleic acids in medicinal plants and their pharmaceutical potential. | Extracell Vesicles Circ Nucl Acids | 2026 | https://conductscience.org/library/papers/42890564 | PubMed |
| 42761173 | Gene therapy for hereditary hematological disorders: From clinical breakthroughs to future horizons. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42761173 | PubMed |
| 42653709 | Targeting Immune Checkpoint Proteins in Cancer Therapy and the Potential of RNAi-Based Immunotherapy. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42653709 | PubMed |
| 42652989 | Zilebesiran, a Small Interfering RNA Therapeutic Targeting Angiotensinogen: Mechanism, Clinical Evidence, Safety, and Implementation Considerations. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42652989 | PubMed |
| 42651807 | Engineering the Future of Precision Medicine: A Comprehensive Guide to RNA Therapeutics. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42651807 | PubMed |
| 42647067 | Medicinal and Crop Protection Chemistry: Breaking Barriers, Building Synergies. | ChemMedChem | 2026 | https://conductscience.org/library/papers/42647067 | PubMed |
| 42646357 | Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells. | Noncoding RNA | 2026 | https://conductscience.org/library/papers/42646357 | PubMed |
| 42629543 | Milk derived exosomes sensitize Gefitinib-resistant lung cancer cells to Pemetrexed via CAV1-mediated endocytosis. | Drug Deliv Transl Res | 2026 | https://conductscience.org/library/papers/42629543 | PubMed |
| 42505414 | LncRNA NR_003508 Boosts Pseudomonas aeruginosa-Induced Autophagy by Facilitating the Conversion of LC3-I to LC3-II and p62 Degradation. | Cells | 2026 | https://conductscience.org/library/papers/42505414 | PubMed |
| 42486096 | Fatty-acid-based antimiR-23b delivery in the DMSXL model: A potential therapeutic strategy for brain dysfunction in myotonic dystrophy type 1. | Cell Rep Med | 2026 | https://conductscience.org/library/papers/42486096 | PubMed |
| 42482156 | miR-335-3p acts as a tumor suppressor in esophageal squamous cell carcinoma and predicts favorable prognosis. | Hereditas | 2026 | https://conductscience.org/library/papers/42482156 | PubMed |
| 42395640 | Bioengineered miR-148a-3p suppresses glycolysis and amino acid homeostasis in hepatocellular carcinoma cells by regulating multiple solute carrier transporters. | Liver Res | 2026 | https://conductscience.org/library/papers/42395640 | PubMed |
| 42381703 | Milk-derived extracellular vesicles loaded with miR-146a-5p as a novel therapeutic strategy for allergic airway inflammation. | Mol Ther Nucleic Acids | 2026 | https://conductscience.org/library/papers/42381703 | PubMed |
| 42373233 | Upregulated Circular RNAs in Gastric Cancer: Target Identification and Tools for Therapeutic Intervention. | Cancer Genomics Proteomics | 2026 | https://conductscience.org/library/papers/42373233 | PubMed |
| 42368742 | Bovine Milk-Derived Extracellular Vesicles as Emerging Drug Delivery Platforms: Current Advances, Applications and Challenges. | J Extracell Biol | 2026 | https://conductscience.org/library/papers/42368742 | PubMed |
| 42356544 | The Role and Therapeutic Potential of the STING Signaling Pathway in the Pathogenesis of Diabetic Nephropathy. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42356544 | PubMed |
| 42293824 | miR-1251-5p inhibits tumorigenesis and metastasis in renal cell carcinoma by targeting MTHFD2. | Transl Androl Urol | 2026 | https://conductscience.org/library/papers/42293824 | PubMed |
| 42218706 | Small interfering RNA (siRNA)-based targeting breast cancer therapy. | Discov Oncol | 2026 | https://conductscience.org/library/papers/42218706 | PubMed |
| 42192969 | miRNA-lncRNA Cross-Regulation Landscape in Cancer: From Molecular Mechanisms to Therapeutic and Diagnostic Applications. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42192969 | PubMed |
Genes41
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35680378
GET https://conductscience.org/api/papers/v1/35680378/references?page=2